Why Early Matters: Data-Driven Strategies to De-Risk OSD Development

Making informed early decisions to accelerate OSD development and predicting problems before they cost you

31

March

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Late-stage surprises continue to drive cost, delay, and complexity in oral solid dosage (OSD) development—especially as pipelines shift toward more complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment have already been committed.

In this panel discussion, GlobalData’s Director of Drugs Intelligence Quentin Horgan is joined by Thermo Fisher Scientific’s Sr Director Global Technical and Scientific Affairs Anil Kane to explore how early insight changes the trajectory of OSD development. The conversation will begin by examining the current state of the OSD market and pipeline – who are the main players, and which CMOs are awarded the most manufacturing deals? How is the R&D pipeline for small molecules shaping up in 2026, and what do approval trends (particularly for first-in-class, breakthrough, and orphan drugs) tell us about this innovative landscape?

The webinar will also focus on how data-driven characterisation, predictive modelling, and Quality by Design approaches enable teams to identify and address risk earlier—when decisions are more flexible and impacts are easier to manage.

Register now to gain practical insight into how earlier, better-informed decisions can reduce rework, improve predictability, and set OSD programmes up for smoother scale-up and commercialisation—before costly surprises emerge

Why Attend:

  • Why early development is a risk-management inflection point and understand how early characterisation and insight shift risk from late, expensive stages to earlier, more manageable ones—changing the economics and success rates of OSD programmes.
  • How data and predictive tools improve early decisions and learn how predictive modelling, Quality by Design principles, and early characterisation reduce trial-and-error, limit rework, and enable smarter formulation and process choices.
  • What predictable, scalable OSD development looks like in practice. Plus, see how early insight leads to smoother scale-up, fewer late-stage surprises, and more efficient paths to commercialisation—benefiting development teams, leaders, and partners alike.
  • How the OSD market is evolving in 2026 as innovative products progress, helping to address high unmet medical needs across a range of therapy areas. Also, understand the key players in OSD development, commercialisation, and contract manufacturing.

Speakers

Select a speaker to learn more

Back
Anil Kane, Ph.D., MBA
Global Head of Technical & Scientific Affairs, Patheon Inc. part of Thermo Fisher Scientific

Dr. Kane has more than 30 years of experience in the science and business of taking molecules through the entire drug development process. His extensive knowledge spans early stage development to scale-up and commercial manufacturing of drug products and includes technical transfers between global sites and drug life cycle management.

Dr. Kane received his Bachelors, Masters and Ph.D. degrees from the Bombay College of Pharmacy, University of Bombay, India, and served as a post-doctoral fellow at the School of Pharmacy, University of Cincinnati, Ohio. He has also earned an executive MBA from Richard Ivey School of Business, University of Western Ontario, Canada. Dr. Kane is a member of various international pharmaceutical professional organizations and is a speaker at many industry events. He has also published many articles in International journals and delivered many talks at meetings and conferences cross the globe.

Next speaker
Back
Quentin Horgan, MSc, BSc
Director of the Drugs and PharmSource databases at GlobalData

Quentin Horgan, MSc, BSc, is the Director of the Drugs and PharmSource databases at GlobalData. His primary responsibilities include reviewing and updating drug information presented on GlobalData’ s drug and manufacturing module, as well as the maintenance of data quality through quality control and timely client support alongside continuous database enhancement. Quentin is also involved in the producing of analytical reports and insights on a range of areas including drug manufacturing, drug development, drug approval, and market trends. He has a firm understanding of all aspects of the pharmaceutical market, drug development, drug manufacturing, and marketing. Quentin holds an MSc in Drugs Discovery and Pharma Management from University College London and a BSc in Biochemistry from the University of Sussex.

Next speaker

Enquiry